A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys), With Ribavirin (Copegus) in Subjects With Genotype 1 Hepatitis C Who Have Not Received Prior Treatment.
Phase of Trial: Phase II
Latest Information Update: 24 Sep 2014
At a glance
- Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms PROVE-1
- Sponsors Vertex Pharmaceuticals
- 24 Sep 2009 A pooled analysis of data from the PROVE 1 and PROVE 2 trials will be presented in a poster session at AASLD 2009 on Nov 3rd.
- 30 Apr 2009 Primary endpoint results published in New England Journal of Medicine 360: 1827-1838, No. 18, 30 Apr 2009.
- 25 Sep 2008 Results will be presented at AASLD in Oct/Nov 2008.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History